GlassScriptPhysician profile
John R Burk
NPI 1700871019
$16,974.45
in general payments reported to CMS, 2019-2025
48 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,107 · 2020: $5,271 · 2021: $4,111 · 2022: $2,436 · 2023: $2,142 · 2024: $383 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Travel and Lodging: $1,034 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.18 |
| Travel and Lodging | $1,033.51 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,307.22 | 2019-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $546.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $267.17 | 2019-2024 | |
| Mylan Specialty L.P. | $262.41 | 2019-2024 | Yupelri, Tobi Podhaler |
| Advanced Respiratory, INC | $227.57 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $224.28 | 2019-2025 | Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $220.55 | 2023-2025 | Uptravi, Opsumit |
| Baxter Healthcare | $144.52 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $129.12 | 2020-2025 | Dificid, Zerbaxa, Recarbrio |
| Grifols USA, LLC | $115.22 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.14 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $95.10 | 2019-2025 | Dupixent |
| Shionogi INC | $93.74 | 2023-2024 | Fetroja |
| Jazz Pharmaceuticals INC. | $82.79 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $81.86 | 2019 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.